Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 701–800 of 999
Zheng, S. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0656
Sim, H., & Choi, M. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0677
The frontline of metabolic dysfunction–associated steatotic liver disease: More to be discovered
Ho, C.-T., Kao, W., & Su, C. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001266
Diabetes Update 2025 – viel Neues
Scherbaum, W. A. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01353-7
Kakita, N., Jono, M., Tsumuro, H., Satake, S., Iwatani, S., Aoi, K., & Katayama, K. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02185-0 · Cited by 1
Clinical perspective on non-sleepy obstructive sleep apnea; to treat or not to treat?
Luu, S., Nanayakkara, B., & Yee, B. J. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2539542
Rebelos, E., & Kounatidis, D. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00273-9
Webeler, P., Kim, G. E., & Paryani, R. (2025) · Cureus · doi:10.7759/cureus.88191 · Cited by 1
Hacking, D. F., Baqar, S., Vaughan, R., & Craven, A. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355289
The Ceiling Is Real: MASH Needs Combination, Not Celebration
Kumar, A., Sharma, P., & Arora, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103147
Safety analysis of tirzepatide in clinical practice
Shnaider, K. O., Kondrakhin, A. P., Maksimov, М. L., Balashova, E. P., Beschetnov, I. D., Akhmadieva, A. A., & Martynova, S. A. (2025) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2508-03
MASLD: Mit GLP-1-Rezeptoragonisten an die Fettleber
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5160-x
新井泰央 (2025) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.21.216
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Gómez-Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502352 · Cited by 1
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
Metabolomic, Lipidomic, and Enterohormone Changes in the Progression from MASLD to MASHPreprint
Rivas, J. A., Murphy, A. C., Prasad, P., Goitom, S. S., Romero, A. S., Enriquez, C. M., Maes, B. B., Akepati, P. R., Garcia, M. A., Lauer, F. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676598
Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome
Drapkina, O. M., & Nedogoda, S. V. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6541 · Cited by 3
Saviano, A., & Serfaty, L. (2025) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)46793-x
Metabolic dysfunction-associated steatotic liver disease and diabetes: Together against the heart
de Souza, M. H. G., Nogueira, P. M. M., & Villela‐Nogueira, C. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i9.109737 · Cited by 2
2025 Clinical Practice Guidelines for Diabetes: Pharmacological Treatment of Type 2 Diabetes
Choi, J. H. (2025) · Journal of Korean Diabetes · doi:10.4093/jkd.2025.26.3.158
TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE
Jędrzejewska-Rzezak, P., Żuczek, A., Dyndał, K., Broda, M., Żuczek, O., Urbańska, K., Szczap, I., Hawryluk, A., Marzec, K., & Mokrzycka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3902
GLP-1 receptor agonist use for obesity in service personnel
Jecks, N., Hughes, C., Macleod, N., & Gifford, R. M. (2025) · BMJ Military Health · doi:10.1136/military-2025-003159
Interdisziplinäre Strategien zur Prävention und Therapie der MASLD
Roehlen, N., Laubner, K., Seufert, J., & Thimme, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2532-5919
Pharmacologic Confounders in Steatotic Liver Disease Outcomes Research—Reply
Ochoa‐Allemant, P., Hubbard, R. A., & Serper, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.5043
Diagnostik und Therapie der Grunderkrankung bei Leberzirrhose
Lang‐Meli, J., & Neumann‐Haefelin, C. (2025) · Springer eBooks · doi:10.1007/978-3-662-70167-6_11
Yoneda, M., Takeuchi, M., Oura, T., & Nakajima, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70225
Self-citationLi, R., Lunares, L., Lambeth, K. E., Alvarado, V. M., Navarrete, J. P., Bizouarn, B. H., & Abdelhakiem, A. K. (2025) · JAPhA Practice Innovations · doi:10.1016/j.japhpi.2025.100082
Zhao, Y., Xie, L., & Chen, T. (2025) · Hepatology International · doi:10.1007/s12072-025-10958-5
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Glucagon-Like Peptide-1 Receptor Agonists
Whitley, H. P. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch13
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetes aktuell · doi:10.1055/a-2665-1304
Yamamori, D., Kitao, T., Masuda, S., Koike, S., Kaketaka, T., Komoda, Y., Nakano, E., Konishi, E., & Ibata, T. (2025) · Cureus · doi:10.7759/cureus.97279 · Cited by 1
Demidova, T. Y., Titova, V. V., Levitskaya, A. N., & Gyozalyan, M. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-456
Chang, J. Y., & Lee, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70401
Quinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
Tirzepatide and Obesity: A Narrative Review
Singh, A., Ahmad, R., Chowdhury, K., Narwaria, M., & Haque, M. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_244_25 · Cited by 1
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803 · Cited by 1
Wang, M., Jiang, Y.-N., Li, P., & Wu, Y.-J. (2025) · Systematic Reviews · doi:10.1186/s13643-025-03011-x · Cited by 1
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8383 · Cited by 3
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Cardiovascular diseases in diabetes
Samhani, C., Poirier, P., Larose, C., & Piché, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00320-4
Metabolic Liver Diseases and Their Management
Creech, L., & Izzy, M. J. (2025) · Springer eBooks · doi:10.1007/978-3-032-07072-2_10
Bhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Campbell, L., Fuest, S., & Jackson, C. D. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-025-10123-6
Wang, Y., WANG, Z., Yan, G., Peng, C., Chen, L., Yan, R., & WANG, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70495 · Cited by 1
MASH and the race for liver antifibrotics
Wills, Q. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2025.1704078 · Cited by 1
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
Juárez-Sosa, J. M., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.017 · Cited by 2
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Li, Q., & Goparaju, P. (2026) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2026.100212
Tailleux, A., & Kamel, S. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76568-0
Bergheim, I., Cadranel, J. F. D., Chen, J., Ding, W., Eferl, R., García‐Ruiz, C., Jaeschke, H., Kazerouni, F., Lonardo, A., Mann, D. A., et al. (2026) · Exploration of Digestive Diseases · doi:10.37349/edd.2026.1005110
Chang, Y. W., Cho, Y. K., Kim, Y. S., Kim, S. E., Cheon, G. J., Kim, J. H., Yang, H. J., Kim, W., Ahn, S. B., Yoon, E. L., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e89 · Cited by 1
Romero-Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F., Cañones, P., et al. (2026) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502639
Midlife weight gain: challenges and solutions
Hung, S., & Adams, K. E. (2026) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000001093 · Cited by 1
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Treatment Decision-making and Weight Loss Expectations for Current Obesity Treatment
Paknikar, S. S., & Shah, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00691-x
Dominguez, C. L., & Rowell, J. V. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2026.01.004
Implementing the 2025 AACE Obesity Algorithm: Bridging Guidelines With Real-World Clinical Practice
Sloan, L. A., Blanchette, J., & Patham, B. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.017
Real world tirzepatide treatment for fatty liver disease
Maung, S. T., & Wong, V. W. (2026) · Hepatology International · doi:10.1007/s12072-026-11065-9
Retatrutide in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2642415
Roberts, S. K., Díaz, L. A., & Castellanos-Fernández, M. I. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.012 · Cited by 1
Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes
Neeland, I. J., & Baskin, R. L. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00004-5
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
Blathra, E., & Liberopoulos, E. N. (2025) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_16_25
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease
Kumar, S., Macedo, M. P., Roden, M., & Kashyap, S. R. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.003
Rajab, I. M., Emara, A., Rakab, M. S., Azim, A. A. A., Aboeldahab, H. A., Abbas, O. F., Rahman, R. A., & Karagozian, R. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05257-1
Alam, U., Rath, S., Ansab, M., Kashif, A., Sethi, F. A., Siddiqui, H. T., Afridi, Z., Burhan, M., Ali, M. A., Moiz, A., et al. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i3.115411
Sillassen, C. D. B., Faltermeier, P., Bjerg, J. L., Andersen, R. K., Petersen, J. J., Andersen, P. B., Kamp, C. B., Karlsson, F., Grand, J., Domínguez, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04824-w · Cited by 3
Diabetes und Metabolische Dysfunktion-assoziierte Steatotische Lebererkrankung
Stefan, N., & Roden, M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01453-y
Tirzepatide in Egypt: A New Era in Type 2 Diabetes and Obesity Management
Ghazi, H. A. (2026) · doi:10.5005/jodec-11035-0006 · Cited by 1
Metabolische Lebererkrankungen bei Adipositas
Horn, P., & Tacke, F. (2026) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2807-4330
Bong, S. H. S., Teh, K. K., & Wong, V. W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0125 · Cited by 3
Tesoro, N. A., Rivera, F. B., Bantayan, N. R. B., Magalong, J. V., Tomada, R., Wong, M. A., Tangco, G. A., Pine, P. L. S., Manha, J. K., Tanni, E. S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101623
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Halley, R., Riley, C. J., Johnson, J., Round, M., Yeh, J., Khan, S., Boyd, A., Haydon, G. H., Mostafa, S. A., Newsome, P. N., et al. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2026-103661
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
Zhang, Z.-R., She, L., Cao, Y., & Chen, Y.-W. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i4.116074
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
Why MASLD Trials Underselect the MENA Region Sites and What Sponsors and Regulators Must Change
El‐Kassas, M., AlNaamani, K. M., Alswat, K., & Younossi, Z. M. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00969-1
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · doi:10.2196/preprints.99738
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model
Li, Y., Wu, Y. N., Wang, G., Zheng, Y., Tong, H., Yang, H., Yu, J., Shi, P., Zheng, Y., Zhou, L., et al. (2026) · European Radiology Experimental · doi:10.1186/s41747-026-00719-w
The Nutrition Landscape in Chronic Liver Disease
McNally, B. B., & Carey, E. J. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09929-z
Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics
Blanco-Echevarría, A., Segovia, R. C., Herraiz, C. G., Izquierdo, B. G., Guadalix, S., Carreras, M. P., Gil, Y. R., Martínez, M. D. C., Amigó, N., D’Avola, D., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343134 · Cited by 1
Xiong, N., Mi, L., Wang, X., Zhang, T., Zhang, G., Chen, Y., Mo, D., Peng, J., Yao, H., Li, S., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178942
Urbanovych, A. M., Sidelnyk, N. Y., & Lishchuk, O. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1717
Wu, J., Lin, Y.-M., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., & Lai, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1769425
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Bazan, A., Plichta, O., & Radzinska, N. (2026) · Cureus · doi:10.7759/cureus.108965 · Cited by 1
Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity
Musaliyar, A., Kumar, N., Terrance, S., Reni, A. R., & Ashwini Aithal, P. (2026) · Journal of Medical Society · doi:10.4103/jms.jms_28_25
The emerging role of branched-chain amino acid metabolism in obesity
Wang, D., Wang, X., & Yang, M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02103-5
Screening for Advanced Liver Disease in Type 2 Diabetes: Time for Systematic Implementation
Solís‐Muñoz, P. (2026) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2026.12025/2026
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.